PDS Biotechnology (NASDAQ:PDSB) Raised to Hold at Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on PDSB. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, PDS Biotechnology has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Trading Down 12.9%

NASDAQ PDSB opened at $1.04 on Monday. The business’s fifty day moving average is $0.52 and its 200-day moving average is $0.80. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. The stock has a market capitalization of $58.49 million, a price-to-earnings ratio of -1.63 and a beta of 1.17. PDS Biotechnology has a one year low of $0.20 and a one year high of $1.55.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Equities research analysts predict that PDS Biotechnology will post -0.47 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently modified their holdings of PDSB. BlackRock Inc. purchased a new stake in shares of PDS Biotechnology during the 2nd quarter valued at approximately $535,000. Bank of New York Mellon Corp bought a new stake in PDS Biotechnology during the 2nd quarter valued at $60,000. Finally, Renaissance Technologies LLC raised its holdings in PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after acquiring an additional 44,100 shares during the period. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers.